Compare AIHS & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIHS | NXL |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | China | United States |
| Employees | N/A | 7 |
| Industry | Finance: Consumer Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 8.3M |
| IPO Year | 2017 | N/A |
| Metric | AIHS | NXL |
|---|---|---|
| Price | $1.26 | $0.43 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 76.5K | ★ 322.1K |
| Earning Date | 02-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.63 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,389,072.00 | N/A |
| Revenue This Year | N/A | $120.99 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.25 | $0.33 |
| 52 Week High | $8.26 | $2.00 |
| Indicator | AIHS | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 42.71 | 51.70 |
| Support Level | $1.10 | $0.37 |
| Resistance Level | $1.35 | $0.46 |
| Average True Range (ATR) | 0.15 | 0.03 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 9.71 | 81.88 |
Senmiao Technology Ltd is a holding company. Along with its subsidiaries, it is engaged in facilitating automobile transactions and offering related services. The group's business activities include providing car rental services to individual customers with lease term no more than twelve months; leasing and servicing of new energy vehicles; offering services to automobile purchasers throughout the purchase process; providing management and related services to Partner Platforms and other companies; automobile financing; and providing other related supporting services to customers. The majority of the group's revenue is generated from its automobile rental business.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.